(Q37301516)

English

Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis

scientific article published on 24 June 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis (English)

1 reference

Europe PubMed Central

19 August 2017

1 reference

based on heuristic

inferred from title

decision analysis

1 reference

based on heuristic

inferred from title

stem cell transplantation

1 reference

based on heuristic

inferred from title

Eva Hellström-Lindberg

13

object named as

Eva Hellstrom-Lindberg

1 reference

Europe PubMed Central

19 August 2017

11

object named as

Pierre Fenaux

1 reference

Europe PubMed Central

19 August 2017

Robert Peter Gale

14

object named as

Robert Peter Gale

1 reference

Europe PubMed Central

19 August 2017

Guillermo Garcia-Manero

5

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

19 August 2017

Martin S. Tallman

19

object named as

Martin S Tallman

1 reference

Europe PubMed Central

19 August 2017

Hans Joachim Deeg

4

object named as

H Joachim Deeg

1 reference

Europe PubMed Central

19 August 2017

Stephanie J. Lee

16

object named as

Stephanie J Lee

1 reference

Europe PubMed Central

19 August 2017

Raphael A Itzykson

9

object named as

Raphael Itzykson

1 reference

Europe PubMed Central

19 August 2017

Everett Peter Greenberg

18

object named as

Peter L Greenberg

1 reference

Europe PubMed Central

19 August 2017

6

object named as

Luca Malcovati

1 reference

Europe PubMed Central

19 August 2017

23

object named as

Corey Cutler

1 reference

Europe PubMed Central

19 August 2017

10

object named as

Lionel Ades

1 reference

Europe PubMed Central

19 August 2017

author name string

John Koreth

1

1 reference

Europe PubMed Central

19 August 2017

Joseph Pidala

2

1 reference

Europe PubMed Central

19 August 2017

Waleska S Perez

3

1 reference

Europe PubMed Central

19 August 2017

Mario Cazzola

7

1 reference

Europe PubMed Central

19 August 2017

Sophie Park

8

1 reference

Europe PubMed Central

19 August 2017

Martin Jadersten

12

1 reference

Europe PubMed Central

19 August 2017

C L Beach

15

1 reference

Europe PubMed Central

19 August 2017

Mary M Horowitz

17

1 reference

Europe PubMed Central

19 August 2017

John F DiPersio

20

1 reference

Europe PubMed Central

19 August 2017

Donald Bunjes

21

1 reference

Europe PubMed Central

19 August 2017

Daniel J Weisdorf

22

1 reference

Europe PubMed Central

19 August 2017

language of work or name

0 references

publication date

24 June 2013

1 reference

Europe PubMed Central

19 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

19 August 2017

31

1 reference

Europe PubMed Central

19 August 2017

21

1 reference

Europe PubMed Central

19 August 2017

2662-2670

1 reference

Europe PubMed Central

19 August 2017

Revised international prognostic scoring system for myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

6 September 2017

Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

6 September 2017

Clinical effect of point mutations in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

6 September 2017

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

6 September 2017

Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

6 September 2017

Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

6 September 2017

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

6 September 2017

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

6 September 2017

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

6 September 2017

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

6 September 2017

Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

6 September 2017

Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

6 September 2017

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

6 September 2017

Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

6 September 2017

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

6 September 2017

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

6 September 2017

Decision analysis on alternative treatment strategies for favorable-prognosis, early-stage Hodgkin's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

6 September 2017

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

6 September 2017

Proposals for the classification of the myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

6 September 2017

Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

6 September 2017

Residual mediastinal mass after treatment of Hodgkin's disease: a decision analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

28 September 2017

Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

26 June 2018

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

26 June 2018

International prognostic scoring system and other prognostic systems for myelodysplastic syndromes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

26 June 2018

Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

26 June 2018

Myelodysplastic syndromes. A multiparametric study of prognostic factors in 336 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

26 June 2018

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

2 September 2018

A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

2 September 2018

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

2 September 2018

Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

2 September 2018

Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

2 September 2018

Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

2 September 2018

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

2 September 2018

Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

2 September 2018

Myelodysplastic syndromes--coping with ineffective hematopoiesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

2 September 2018

Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

2 September 2018

Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

2 September 2018

Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825320

2 September 2018

Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/23797000

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/23797000

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23797000

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program

1 reference

https://pubmed.ncbi.nlm.nih.gov/23797000

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myelodysplastic syndromes: a scoring system with prognostic significance

1 reference

https://pubmed.ncbi.nlm.nih.gov/23797000

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system

1 reference

https://pubmed.ncbi.nlm.nih.gov/23797000

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/23797000

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Life expectancy in primary myelodysplastic syndromes: a prognostic score based upon histopathology from bone marrow biopsies of 569 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23797000

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The myelodysplastic syndromes: an analysis of prognostic factors in 226 cases from a single institution

1 reference

https://pubmed.ncbi.nlm.nih.gov/23797000

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23797000

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Application of the International Scoring System for myelodysplasia to M.D. Anderson patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23797000

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23797000

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and

1 reference

https://pubmed.ncbi.nlm.nih.gov/23797000

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2012.46.8652

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37301516&oldid=1835259559"